Evidence map›Paper›PMID 32792861›Full record

ReviewInternational journal of biological sciences2020

miRNA-based biomarkers, therapies, and resistance in Cancer.

Boxue He, Zhenyu Zhao, Qidong Cai, Yuqian Zhang, Pengfei Zhang, Shuai Shi, Hui Xie, Xiong Peng, Wei Yin, Yongguang Tao and 1 more

Open access · goldAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in International journal of biological sciences, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 366 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
366citing papers in PubMed, 2 pooled it
20.0field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

366 citing papers in PubMed, 2 syntheses or guidelines pooled it, 600 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Review
  4. Review
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Review
  16. Article
  17. Article
  18. Review
  19. Review
  20. Article

306 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 2 institutions in 1 country.

Boxue HeDepartment of Thoracic Surgery, The Second Xiangya Hospital, Central South University, Changsha, Hunan 410011, China.
Zhenyu ZhaoDepartment of Thoracic Surgery, The Second Xiangya Hospital, Central South University, Changsha, Hunan 410011, China.
Qidong CaiDepartment of Thoracic Surgery, The Second Xiangya Hospital, Central South University, Changsha, Hunan 410011, China.
Yuqian ZhangDepartment of Thoracic Surgery, The Second Xiangya Hospital, Central South University, Changsha, Hunan 410011, China.
Pengfei ZhangDepartment of Thoracic Surgery, The Second Xiangya Hospital, Central South University, Changsha, Hunan 410011, China.
Shuai ShiDepartment of Thoracic Surgery, The Second Xiangya Hospital, Central South University, Changsha, Hunan 410011, China.
Hui XieDepartment of Thoracic Surgery, The Second Xiangya Hospital, Central South University, Changsha, Hunan 410011, China.
Xiong PengDepartment of Thoracic Surgery, The Second Xiangya Hospital, Central South University, Changsha, Hunan 410011, China.
Wei YinDepartment of Thoracic Surgery, The Second Xiangya Hospital, Central South University, Changsha, Hunan 410011, China.
Yongguang TaoDepartment of Thoracic Surgery, The Second Xiangya Hospital, Central South University, Changsha, Hunan 410011, China.
Xiang WangDepartment of Thoracic Surgery, The Second Xiangya Hospital, Central South University, Changsha, Hunan 410011, China.
Central South University · CNSecond Xiangya Hospital of Central South University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

MicroRNAs (miRNAs), small non-coding RNAs (ncRNAs) of about 22 nucleotides in size, play important roles in gene regulation, and their dysregulation is implicated in human diseases including cancer. A variety of miRNAs could take roles in the cancer progression, participate in the process of tumor immune, and function with miRNA sponges. During the last two decades, the connection between miRNAs and various cancers has been widely researched. Based on evidence about miRNA, numerous potential cancer biomarkers for the diagnosis and prognosis have been put forward, providing a new perspective on cancer screening. Besides, there are several miRNA-based therapies among different cancers being conducted, advanced treatments such as the combination of synergistic strategies and the use of complementary miRNAs provide significant clinical benefits to cancer patients potentially. Furthermore, it is demonstrated that many miRNAs are engaged in the resistance of cancer therapies with their complex underlying regulatory mechanisms, whose comprehensive cognition can help clinicians and improve patient prognosis. With the belief that studies about miRNAs in human cancer would have great clinical implications, we attempt to summarize the current situation and potential development prospects in this review.

Indexed as

Drug Resistance, NeoplasmMolecular Targeted TherapyAnimalsBiomarkers, TumorHumansMicroRNAsNeoplasmsBiomarkers, TumorMicroRNAsCancerCancer therapy resistanceMicroRNAsmiRNA-based biomarkersmiRNA-based therapies

Identifiers

PMID32792861
PMCPMC7415433
OpenAlexW3044903507

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.